









市場行情
/
股票
/
nasdaq-zvra
/

Zevra Therapeutics Inc

ZVRA

8.870USD

+0.230+2.66%

收盤 12/26, 16:00（美東）報價延遲15分鐘

498.65M總市值

14.70本益比TTM



Zevra Therapeutics Inc

8.870

+0.230+2.66%

概覽公司財務分析

概覽

公司

財務

分析

關於 Zevra Therapeutics Inc 公司

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Zevra Therapeutics Inc簡介



公司代碼ZVRA

公司名稱Zevra Therapeutics Inc

上市日期Apr 16, 2015

CEOMcfarlane (Neil F)

員工數量59

證券類型Ordinary Share

年結日Apr 16

公司地址1180 Celebration Boulevard

城市CELEBRATION

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編34747

電話13219393416

網址https://zevra.com/

公司代碼ZVRA

上市日期Apr 16, 2015

CEOMcfarlane (Neil F)

Zevra Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Neil F. Mcfarlane

President, Chief Executive Officer, Director

222.02K

+15.93%

Mr. John B. Bode

Independent Director

45.00K

+12.50%

Mr. Joshua Schafer

Executive Vice President - Business Development, Chief Commercial Officer

28.33K

-27.04%

Mr. Thomas D. (Tom) Anderson

Independent Director

Mr. R. LaDuane Clifton, CPA

Chief Financial Officer, Treasurer

Dr. Alvin Shih, M.D.

Independent Director

Dr. Adrian Quartel, M.D.

Chief Medical Officer

Ms. Tamara A. (Seymour) Favorito, CPA

Independent Chairman of the Board

Mr. Corey Watton

Independent Director

Mr. Rahsaan W. Thompson

Chief Legal Officer, Secretary, Compliance Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. Neil F. Mcfarlane

President, Chief Executive Officer, Director

222.02K

+15.93%

Mr. John B. Bode

Independent Director

45.00K

+12.50%

Mr. Joshua Schafer

Executive Vice President - Business Development, Chief Commercial Officer

28.33K

-27.04%

Mr. Thomas D. (Tom) Anderson

Independent Director

Mr. R. LaDuane Clifton, CPA

Chief Financial Officer, Treasurer

Dr. Alvin Shih, M.D.

Independent Director

收入明細

FY2025Q2

FY2024

FY2023

FY2022

FY2021

FY2020

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

25.88M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.53%

Woodline Partners LP

6.17%

The Vanguard Group, Inc.

5.48%

Adage Capital Management, L.P.

3.95%

Nantahala Capital Management, LLC

3.50%

其他

74.37%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.53%

Woodline Partners LP

6.17%

The Vanguard Group, Inc.

5.48%

Adage Capital Management, L.P.

3.95%

Nantahala Capital Management, LLC

3.50%

其他

74.37%

股東類型

持股股東

佔比

Hedge Fund

24.62%

Investment Advisor

24.56%

Investment Advisor/Hedge Fund

16.60%

Research Firm

3.61%

Private Equity

1.62%

Individual Investor

0.80%

Venture Capital

0.33%

Bank and Trust

0.16%

Pension Fund

0.14%

其他

27.57%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

256

37.37M

66.37%

-1.07M

2025Q2

239

33.85M

61.90%

-4.28M

2025Q1

252

39.54M

72.42%

-1.74M

2024Q4

247

37.53M

70.32%

+3.07M

2024Q3

232

32.67M

61.46%

+11.34M

2024Q2

214

19.77M

45.38%

+395.88K

2024Q1

213

17.66M

40.45%

-265.50K

2023Q4

207

16.32M

37.86%

+175.17K

2023Q3

203

14.77M

38.14%

-620.11K

2023Q2

208

12.57M

36.97%

-1.13M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

3.72M

6.62%

-68.78K

-1.82%

Jun 30, 2025

Woodline Partners LP

4.62M

8.22%

+51.00

+0.00%

Jun 30, 2025

The Vanguard Group, Inc.

2.95M

5.26%

+126.84K

+4.49%

Jun 30, 2025

Adage Capital Management, L.P.

4.17M

7.42%

+550.00K

+15.20%

Jun 30, 2025

Nantahala Capital Management, LLC

1.47M

2.62%

Jun 30, 2025

Fidelity Management & Research Company LLC

2.20M

3.92%

+10.59K

+0.48%

Jun 30, 2025

State Street Investment Management (US)

1.24M

2.21%

+65.11K

+5.53%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.24M

2.21%

+9.28K

+0.75%

Jun 30, 2025

Legal & General Investment Management Ltd.

935.68K

1.67%

+197.94K

+26.83%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Propel Opportunities ETF

2.21%

State Street SPDR S&P Pharmaceuticals ETF

1.46%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.04%

Federated Hermes MDT Small Cap Core ETF

0.19%

iShares Micro-Cap ETF

0.11%

ProShares Ultra Nasdaq Biotechnology

0.06%

Invesco Nasdaq Biotechnology ETF

0.06%

iShares Biotechnology ETF

0.05%

Vanguard US Momentum Factor ETF

0.05%

iShares Russell 2000 Growth ETF

0.03%

Simplify Propel Opportunities ETF

佔比2.21%

State Street SPDR S&P Pharmaceuticals ETF

佔比1.46%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.04%

Federated Hermes MDT Small Cap Core ETF

佔比0.19%

iShares Micro-Cap ETF

佔比0.11%

ProShares Ultra Nasdaq Biotechnology

佔比0.06%

Invesco Nasdaq Biotechnology ETF

佔比0.06%

iShares Biotechnology ETF

佔比0.05%

Vanguard US Momentum Factor ETF

佔比0.05%

iShares Russell 2000 Growth ETF

佔比0.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Zevra Therapeutics Inc的前五大股東是誰？



Zevra Therapeutics Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：3.72M
佔總股份比例：6.62%。
Woodline Partners LP
持有股份：4.62M
佔總股份比例：8.22%。
The Vanguard Group, Inc.
持有股份：2.95M
佔總股份比例：5.26%。
Adage Capital Management, L.P.
持有股份：4.17M
佔總股份比例：7.42%。
Nantahala Capital Management, LLC
持有股份：1.47M
佔總股份比例：2.62%。